Crinetics Pharmaceuticals, Inc. (CRNX)

Market Cap	3.35B
Revenue (ttm)	4.01M
Net Income (ttm)	-214.53M
Shares Out	77.93M
EPS (ttm)	-3.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	609,025
Open	42.36
Previous Close	43.01
Day's Range	42.20 - 44.25
52-Week Range	15.76 - 49.58
Beta	0.62
Analysts	Strong Buy
Price Target	56.25 (+30.91%)
Earnings Date	May 2, 2024

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2018
• Employees: 290
• Stock Exchange: NASDAQ
• Ticker Symbol: CRNX

Financial Performance

In 2023, CRNX's revenue was $4.01 million, a decrease of -15.28% compared to the previous year's $4.74 million. Losses were -$214.53 million, 30.9% more than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for CRNX stock is "Strong Buy." The 12-month stock price forecast is $56.25, which is an increase of 30.91% from the latest price.

Price Target

$56.25

(30.91% upside)

Analyst Consensus: Strong Buy